CLINICAL RESEARCH TO UNDERSTAND ACQUIRED IMMUNITY TO DENGUE VIRUSES
Funder
National Health and Medical Research Council
Funding Amount
$841,953.00
Summary
Dengue, the commonest arboviral disease of humans, is caused by any of the four serotypes of dengue virus (DENV-1-4). This clinical research project will explore how acquired immunity to dengue viruses is expressed. The results will help dengue vaccine developers make better vaccines for use in Australian travellers and in dengue endemic countries in SE Asia.
Profiling The Specificity Of The Neutralizing Antibody Response In People Who Have Long Term Protection From Developing Chronic HCV
Funder
National Health and Medical Research Council
Funding Amount
$372,972.00
Summary
Hepatitis C causes chronic liver disease in over 150 million people world-wide. In this study we will determine the qualities of the immune response that protect individuals from HCV infection and reinfection. The outcomes of this study will provide a pathway for the development of vaccines that elicit protective immune signatures.
Viral infections that mothers catch during pregnancy still cause much illness in babies either in the womb, or after birth. One of these infections called CMV causes more babies to be born with malformation in Australia than any other infection, and is second only to cerebral palsy as a cause of serious problems in babies. Our studies are examining CMV in mothers and babies, leading to better diagnostic tests, researching use of existing and new antiviral drugs to reduce infection in these mothe ....Viral infections that mothers catch during pregnancy still cause much illness in babies either in the womb, or after birth. One of these infections called CMV causes more babies to be born with malformation in Australia than any other infection, and is second only to cerebral palsy as a cause of serious problems in babies. Our studies are examining CMV in mothers and babies, leading to better diagnostic tests, researching use of existing and new antiviral drugs to reduce infection in these mothers and babies.Read moreRead less
Resolving Human Immunodeficiency Virus (HIV) Transmission
Funder
National Health and Medical Research Council
Funding Amount
$745,213.00
Summary
To increase the breadth of HIV prevention strategies, it is imperative that we biologically understand how HIV enters our bodies. Through two unique clinical cohorts, we will determine why circumcision is protective and how a commonly acquired sexual transmitted infection (human papilloma virus) can increase HIV transmission.
A Universal Prophylactic Vaccine For Hepatitis C Virus
Funder
National Health and Medical Research Council
Funding Amount
$643,337.00
Summary
Hepatitis C Virus (HCV) infects 200 million people world wide. An effective vaccine to prevent HCV is urgently needed but must afford protection against the 7 diverse genotypes. In this project grant we aim to further define the quality of the immune response that is generated by a novel HCV vaccine candidate that generates pan-genotypic immunity, its unique structural features, and methods of manufacturing so that it can be tested in a future phase I human clinical trial.
Oral Human Papillomavirus Infection In Head And Neck Cancers And The General Population.
Funder
National Health and Medical Research Council
Funding Amount
$422,800.00
Summary
Mucosal cancers of the head and neck are the sixth most common type of cancer worldwide and are increasing in Australia. Human papillomaviruses (HPV), which are the major cause of cervical cancer and the cause of 5% of all human cancers, have recently also been implicated as a cause of some types of head and neck cancer, especially in patients younger than 50 years. In this project we will investigate how HPV infection regulates the expression of key genes in cancers of the head and neck, and ho ....Mucosal cancers of the head and neck are the sixth most common type of cancer worldwide and are increasing in Australia. Human papillomaviruses (HPV), which are the major cause of cervical cancer and the cause of 5% of all human cancers, have recently also been implicated as a cause of some types of head and neck cancer, especially in patients younger than 50 years. In this project we will investigate how HPV infection regulates the expression of key genes in cancers of the head and neck, and how that affects prognosis of this disease.Read moreRead less
Highly Pathogenic Avian Influenza (HPAI) - Improved Diagnosis With Quality Assurance Of Serological & Molecular Diagnost
Funder
National Health and Medical Research Council
Funding Amount
$249,019.00
Summary
This project aims to produce Quality Assurance (QA) algorithms to ensure accurate diagnosis of highly pathogenic avian influenza (HPAI) using serological and molecular techniques. The project will assess HPAI diagnosis accurately within the setting of other circulating respiratory illnesses, utilising a new HPAI module, ,in combination with existing modules within the Royal College of Pathologists of Australia (RCPA) Serology Quality Assurance Program (SQAP). This will ensure rapid, cost-efficie ....This project aims to produce Quality Assurance (QA) algorithms to ensure accurate diagnosis of highly pathogenic avian influenza (HPAI) using serological and molecular techniques. The project will assess HPAI diagnosis accurately within the setting of other circulating respiratory illnesses, utilising a new HPAI module, ,in combination with existing modules within the Royal College of Pathologists of Australia (RCPA) Serology Quality Assurance Program (SQAP). This will ensure rapid, cost-efficient improvements in diagnostics by utilizing existing infrastructure. The key elements of the project are: Introduction of quality assurance processes to ensure accurate diagnosis and to evaluate existing and developing laboratory testing procedures, test accuracy, and result interpretation; Involvement of human and veterinary laboratories in the QA and development processes; Production of suitable antigenic material through molecular virology as targets for HPAI antibody and molecular diagnostics in QA programs. This will thereby allow large quantities of non-infectious material for HPAI QA assessment of serological and molecular assays around Australia, using baculovirus expressed antigens and cloned gene targets respectively. These projects are designed within a short (<12 month) time frame in order to fulfil the needs of the Australian community in controlling the developing HPAI avian pandemic, and the possible human pandemic. Significant positive outcomes in the next six months are assured by the existence of current QA processes, experience in influenza research already available in the human and animal health laboratories involved, the research records of the groups, and the close existing linkages between the research, QA, diagnostic and avian virology groups.Read moreRead less
Prophylactic Vaccine Development For The Elimination Of Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$936,752.00
Summary
A vaccine that prevents Hepatitis C is urgently needed to prevent infection and assist with global HCV elimination targets. This project grant will advance world-leading HCV vaccine candidates that generate both humoral and cellular immunity for clinical development.
Novel HIV-1 Glycoprotein Vaccines With Enhanced Presentation Of Broad Neutralization Epitopes
Funder
National Health and Medical Research Council
Funding Amount
$743,682.00
Summary
A prophylactic vaccine represents the best strategy for blocking HIV-1 transmission but one is not yet available. Current antiviral vaccines rely on neutralizing antibodies (NAbs) that block infection, however, current HIV-1 vaccine formulations do not induce broadly reactive NAbs (bNAbs). We have discovered a novel HIV-1 glycoprotein vaccination candidate with enhanced presentation of bNAb epitopes. We propose to determine if this vaccine induces effective bNAbs in experimental animals.
Roles Of The Hepatitis C Virus Glycoprotein E2 Variable Regions In Virus Entry, Immunogenicity And Immune Evasion.
Funder
National Health and Medical Research Council
Funding Amount
$682,820.00
Summary
Hepatitis C Virus infects 200 million people world-wide with over 200,000 Australians infected with the disease. This project will examine how the surface proteins of HCV change their shape to evade antibody responses and how this effects the outcome of infection. We will further characterize a vaccine that elicits protective immunity to HCV to identify the optimal formulation for clinical trials.